Difference between revisions of "Blinatumomab (Blincyto)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Bi-specific T-cell engager (BiTE) that targets CD19. ==Diseases for which it is used== *Acute lymphocytic leukemia ==History of changes in FDA in...") |
m |
||
| Line 13: | Line 13: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Intravenous | + | [[Category:Intravenous chemotherapy]] |
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
Revision as of 00:48, 13 November 2014
Mechanism of action
Bi-specific T-cell engager (BiTE) that targets CD19.
Diseases for which it is used
History of changes in FDA indication
- 7/1/2014: Granted FDA breakthrough therapy designation "for adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)."
Also known as
MT103